Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Patient perspectives on symptoms and impacts in Crohn's disease: results from qualitative research. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i265.
Gibble TH, Kosa K, Basnyat B, Martin S, Moses R, Dubinsky M. Cognitive debriefing of a patient-reported outcome measure for abdominal pain and loose stool frequency in Crohn's disease. Poster presented at the European Crohn's and Colitis Organisation (ECCO) 2024; February 21, 2024. Stockholm, Sweden. [abstract] J Crohns Colitis. 2024 Jan; 18(Suppl 1):i572.
Vickers AD, Mody RR, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 10th Congress of the European Crohn's and Colitis Organization; February 18, 2015. Barcelona, Spain. [abstract] J Crohns Colitis. 2015 Feb 2; 9(Suppl 1):S357-8. doi: 10.1093/ecco-jcc/jju027.672
Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0
Goyal RK, Patel JG, Sansgiry SS. Pharmacists perceptions of drug reimbursement rates and processing times among managed care plans. Drug benefit trends: a publication for manager and health professionals in hmos and ppos. 2010;22(4):116-20.